DPP4 and cancer: In our own work, we have shown that changes in hydroxylation or glycosylation have dramatic effects on the ability of apigenin to upregulate CD26, and thus potentially affect hallmarks of cancer (Lefort and Blay, 2011; Lefort et al., 2020).